Survey Suggests Price Isn’t Payers’ Only GLP-1 Concern

Jun 12
Jun 12, 2025

A survey from the Pharmaceutical Strategies Group (PSG) released on June 10 found that 90% of health plans and employers were moderately or very concerned about the affordability of GLP-1 medications for obesity, up 10% from last year’s report. The cost is not the only issue, though, as 42% of respondents that do not currently cover the medications said they would not cover them for obesity at any price.

Morgan Lee, Ph.D., PSG’s senior director of research and strategy, says the findings suggest that many payers still have questions about the best way to treat obesity even though the American Medical Association recognized obesity as a disease in 2013.
Read more
© 2025 MMIT

Tim Casey

Tim has been a reporter and editor for newspapers, websites and magazines for more than 20 years, including 10 years covering health care business topics. He has a deep knowledge of the managed care industry and pharmacy benefit management. He also has experience covering medical conferences and clinical and legislative health care issues. In 2014, the Society for Advancing Business Editing and Writing selected Tim as one of 15 journalists to participate in a national symposium on the Affordable Care Act. Tim has a B.A. in Psychology from the University of Notre Dame and an M.B.A. from Georgetown University.